LCM Biosensor Technologies, Inc.
Next generation metabolic biomarkers sensing technology In Prevention
and Management of Chronic Disease
and Management of Chronic Disease
Just type your contacts
It's totally free
About Us
LCM Biosensor Technologies is a deep -tech life -sciences NY based company that is transforming the way people monitor their health using a sensor-based wearable technology that detects the earliest stages of diabetes and other life-threatening conditions.
LCM has discovered an innovative needle -free biomarkers monitoring platform using an optical-osmotic transducer that reads blood sugar levels continuously through the skin matching the accuracy of an FDA approved finger-prick glucose meters and provides real-time tracking of various health biomarkers at the tissue, cellular, and molecular levels.
The primary focus is on continuous glucose monitoring. The goal is to move from a hardware – centric wearable to a service - centric “Healthspan Compass” that empowers users – particularly those without confirmed diabetic issues - to detect early warning signs and optimize their health through data-driven lifestyle corrections.
Our Global Mission is to help people to predict early and prevent Diabetes and other chronic conditions to extend the healthspan - the duration of life free from chronic diseases - using LCM Biosensor technologies.
Problem
Prediction Diabetes – Unsolved World Problem.
Diabetes affects around 600 million people across the globe including 38 million in the USA. Type 2 Diabetes is a major risk factor for the whole host of lethal diseases (cardiovascular, renal, metabolic) which collectively are the leading cause of deaths across the globe, killing 20 M people each year.
Diabetes places significant pressure on healthcare costs. The total annual cost of diabetes in the U.S. in 2022 was $413 billion. People with diagnosed diabetes now account for one of every four healthcare dollars spent in the U.S.
NEEDLE – FREE BIOMARKERS MONITORING PLATFORM
The solution to this one of most dangerous life-threatening conditions is a service-centric ecosystem that helps users to detects the earliest stages of diabetes using a portable needle –free glucose monitoring device which has been on of the biggest ambitions in wearables for decades.
Diabetes affects around 600 million people across the globe including 38 million in the USA. Type 2 Diabetes is a major risk factor for the whole host of lethal diseases (cardiovascular, renal, metabolic) which collectively are the leading cause of deaths across the globe, killing 20 M people each year.
Diabetes places significant pressure on healthcare costs. The total annual cost of diabetes in the U.S. in 2022 was $413 billion. People with diagnosed diabetes now account for one of every four healthcare dollars spent in the U.S.
NEEDLE – FREE BIOMARKERS MONITORING PLATFORM
The solution to this one of most dangerous life-threatening conditions is a service-centric ecosystem that helps users to detects the earliest stages of diabetes using a portable needle –free glucose monitoring device which has been on of the biggest ambitions in wearables for decades.
Solution
We have invented cutting edge non-invasive glucose sensing technology that allows to monitor blood glucose levels by real time measurement of the osmotic pressure of the intercellular substance of the skin epidermis using an osmotic transducer placed on the skin surface.
The revolutionary disruptive technology provides noninvasive continuous concurrent real-time tracking of various biomarkers at the tissue, cellular, and molecular levels, including blood glucose level, calorie intake and others using an optical-osmotic transducer placed on the skin surface.
Patents were filed in multiple countries USA, China, EU, India: US patent app. No.17/747,380 and US Patent No. US 11,925,463 B2 March, 2024.
The revolutionary disruptive technology provides noninvasive continuous concurrent real-time tracking of various biomarkers at the tissue, cellular, and molecular levels, including blood glucose level, calorie intake and others using an optical-osmotic transducer placed on the skin surface.
Patents were filed in multiple countries USA, China, EU, India: US patent app. No.17/747,380 and US Patent No. US 11,925,463 B2 March, 2024.
Status
Our solution has been validated in a proof-of-concept study of over 70+ healthy and diabetic subjects and over 600 tests, including 272 tests with 62 diabetic subjects. The pre-production prototype (TRL7) has been tested and is ready for mass production.
Diabetes Prediction – World’s Biggest Health Challenge.
World diabetic population
2021: 537 million
2030: 643 million (projected)
→ 541 million adults are at increased risk of developing Type 2 Diabetes
→ 88% of patients are unaware that they are pre-diabetic
→ 88% of patients are unaware that they are pre-diabetic
Type 2 Diabetes is a preventable disease – IF detected early, and a needle free glucose sensing technology must be invented for detecting diabetes early.
2021: 537 million
2030: 643 million (projected)
→ 541 million adults are at increased risk of developing Type 2 Diabetes
→ 88% of patients are unaware that they are pre-diabetic
→ 88% of patients are unaware that they are pre-diabetic
Type 2 Diabetes is a preventable disease – IF detected early, and a needle free glucose sensing technology must be invented for detecting diabetes early.
The Product
Provides continuous noninvasive real-time tracking of various metabolic biomarkers at the tissue, cellular and molecular levels:
• Blood glucose;
• Molecular biomarkers: triglycerides, carbohydrates, hyaluronic acid and others;
• Cellular metabolic rate & Calorie intake;
• Blood pressure / Blood Oxygen.
Healthcare and Wellbeing/Healthy Lifestyle applications:
Diagnostic & monitoring biomarkers - self-monitoring, early diagnostics & prevention of diabetes and related chronic diseases:
• metabolic and closely associated cardiovascular and renal;
• breast cancer;
• skin health & aging;
Nutrition as a prevention – monitoring the rate of cellular metabolism and calorie intake.
A portable needle-free biomarkers monitoring platform using proprietary optical-osmotic transducer that reads blood sugar levels continuously through the skin with the accuracy of an FDA approved glucose meters and provides real-time tracking of various health biomarkers at the tissue, cellular, and molecular levels: HbA1c, Cellular metabolism rate, Calorie intake and others.The summary of the glucose readings accuracy study is available here https://drive.google.com/drive/folders/1ZIIzNEest-7CMlahpFgKC3R-lA2ofTYB
The ecosystem of Preventative Healthcare and Wellness.
A service – centric LCM Healthspan Compassis a Real Time Laboratory on the wrist for needle-free tracking health biomarkers that empowers users to detect early stages of chronic diseases and optimize their health through data-driven lifestyle corrections.
•Early Prediction and Prevention Diabetes and related conditions;
•Obesity-related diseases prediction & prevention;
•Nutrition as a Prevention;
•Breast Cancer early detection.
The ecosystem of Preventative Healthcare and Wellness.
A service – centric LCM Healthspan Compassis a Real Time Laboratory on the wrist for needle-free tracking health biomarkers that empowers users to detect early stages of chronic diseases and optimize their health through data-driven lifestyle corrections.
•Early Prediction and Prevention Diabetes and related conditions;
•Obesity-related diseases prediction & prevention;
•Nutrition as a Prevention;
•Breast Cancer early detection.
The Solution: Optical-Osmotic Transducer
LCM discovered a breakthrough technology that allows to overcome the technological barrier and monitor blood glucose level by noninvasive high-precision measurement
of the osmotic pressure of the intercellular substance of the skin epidermis in real time.
An optical–osmotic transducer placed on the skin surface converts
the change in intercellular osmotic pressure into an electric signal.
of the osmotic pressure of the intercellular substance of the skin epidermis in real time.
An optical–osmotic transducer placed on the skin surface converts
the change in intercellular osmotic pressure into an electric signal.
TECHNOLOGY
A New Approach
It is well known that the progress in noninvasive glucose monitoring R&D is hindered by limited detection sensitivity of the conventional spectroscopy methods, that is, the absorption spectra of glucose in water is almost indistinguishable from the absorption spectra of water alone. In addition, because the skin is not a homogeneous and stable optical medium, this problem becomes extremely difficult to overcome.
We have developed a different approach. Through re-examining the basic physics of glucose interaction with the living tissue, we first built a scientific groundwork of Skin Biophysics, or the Physics of Intercellular Substance – Living Condensed Matter (LCM) Physics.
We discovered that glucose interactionswith the hyaluronic acid under physiological conditions leads to the formation of a living condensed matter that acts as a natural biosensor with the selectivity to glucose molecules and sensitivity to heat energy and functions as a glucose sensing calorimeter that converts glucose concentration change into osmotic pressure change.
We have developed a different approach. Through re-examining the basic physics of glucose interaction with the living tissue, we first built a scientific groundwork of Skin Biophysics, or the Physics of Intercellular Substance – Living Condensed Matter (LCM) Physics.
We discovered that glucose interactionswith the hyaluronic acid under physiological conditions leads to the formation of a living condensed matter that acts as a natural biosensor with the selectivity to glucose molecules and sensitivity to heat energy and functions as a glucose sensing calorimeter that converts glucose concentration change into osmotic pressure change.
The Prototype – Proof of Concept Clinical Study
The accuracy of LCM measurements is within
FDA-required limits
FDA-required limits
The Prototype – Proof of Concept Clinical Study
Results comparable to an FDA-approved
Results comparable to an FDA-approved
The Prototype – Proof of Concept Clinical Study
Results comparable to an FDA-approved
Results comparable to an FDA-approved
The Prototype – Proof of Concept Clinical Study
Results comparable to an FDA-approved
Results comparable to an FDA-approved
Contact us
Email: info@lcmbiosensor.com
Address: USA 20 Maple Avenue, East Setauket, NY 11733
Address: USA 20 Maple Avenue, East Setauket, NY 11733
